Jennifer Knight, MD, MS, FACLP

Associate Professor, Psychiatry and Behavioral Medicine and Microbiology & Immunology

Locations

Psychiatry and Behavioral Medicine

Contact Information

Learn more about the Knight Biobehavioral Oncology Laboratory

Biography

Dr. Knight completed her undergraduate training at the University of Wisconsin-Madison and her medical training at the Medical College of Wisconsin. She completed her residency training in a combined Internal Medicine and Psychiatry program at Rush University in Chicago, and is double board certified in both specialties. She also completed a post-doctoral research fellowship in psychoneuroimmunology at the University of Rochester Medical Center.

Research Interests

Dr. Knight’s research interests involve investigating the physiologic and immunologic effects that account for the relationship between psychosocial factors and clinical outcomes in hematopoietic stem cell transplant recipients. Clinically, she is the Medical Director of the Psycho-Oncology Program at Froedtert and MCW and specializes in general and psycho-oncology psychosomatic medicine consultation. She sees patients at the MCW Cancer Center and at Froedtert Hospital. She is on faculty at the Neuroscience Research Center and is also a Clinical Member of the MCW Cancer Center in the Transplantation Biology and Immunotherapy Research Program.

Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism.

(Satilmis H, Verheye E, Vlummens P, Oudaert I, Vandewalle N, Fan R, Knight JM, De Beule N, Ates G, Massie A, Moreaux J, Maes A, De Bruyne E, Vanderkerken K, Menu E, Sloan EK, De Veirman K.) J Pathol. 2022 Oct 17 PMID: 36245401 10/18/2022
Associations between socioeconomic status and bispecific LV20.19 CAR T cell therapy outcomes.

(Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN.) Haematologica. 2022 Oct 06 PMID: 36200427 10/07/2022
Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions.

(Taylor MR, Steineck A, Lahijani S, Hall AG, Jim HSL, Phelan R, Knight JM.) Transplant Cell Ther. 2022 Oct 05 PMID: 36208728 10/09/2022
New-onset hallucinations with amiodarone: a case report.

(Molinaro J, DeVries P, Ha J, Knight JM.) Ann Gen Psychiatry. 2022 Aug 24;21(1):34 PMID: 36002899 PMCID: PMC9400302 SCOPUS ID: 2-s2.0-85137030748 08/25/2022
The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation.

(Taylor MR, Hillard CJ, Drobyski WR, Szabo A, Johnson BD, Zhu F, Raison CL, Cole SW, Knight JM.) Brain Behav Immun Health. 2022 Aug;23:100480 PMID: 35757656 PMCID: PMC9213229 SCOPUS ID: 2-s2.0-85133379996 06/28/2022
Perceptions and Experiences of Hematopoietic Cell Transplantation Patients During the COVID-19 Pandemic.

(Mohanraj L, Elswick RK Jr, Buch M, Knight JM, Guidry J.) Semin Oncol Nurs. 2022 Aug;38(4):151257 PMID: 35379527 PMCID: PMC8907028 SCOPUS ID: 2-s2.0-85127530657 04/06/2022
Impact of the COVID-19 pandemic on cancer patients and psycho-oncology providers: Perspectives, observations, and experiences of the American Psychosocial Oncology Society membership.

(McAndrew NS, Strong Y, Morris KJ, Sannes TS, Pirl WF, Cole S, Mohanraj L, Knight JM.) Psychooncology. 2022 Jun;31(6):1031-1040 PMID: 35102653 SCOPUS ID: 2-s2.0-85124553620 02/02/2022
Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy.

(Knight JM, Szabo A, Arapi I, Wu R, Emmrich A, Hackett E, Sauber G, Yim S, Johnson B, Hari P, Schneider D, Dropulic B, Cusatis RN, Cole SW, Hillard CJ, Shah NN.) Commun Med (Lond). 2022 May 12;2(1):49 PMID: 36372801 11/14/2022
Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol.

(Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM.) Yale J Biol Med. 2022 Mar;95(1):45-56 PMID: 35370486 PMCID: PMC8961707 SCOPUS ID: 2-s2.0-85127524780 04/05/2022
Biobehavioral Implications of Covid-19 for Transplantation and Cellular Therapy Recipients.

(Knight JM, Taylor MR, Rentscher KE, Henley EC, Uttley HA, Nelson AM, Turcotte LM, McAndrew NS, Amonoo HL, Mohanraj L, Kelly DL, Costanzo ES.) Front Immunol. 2022;13:877558 PMID: 35865530 PMCID: PMC9295749 SCOPUS ID: 2-s2.0-85134257906 07/23/2022
Biobehavioral Pathways and Cancer Progression: Insights for Improving Well-Being and Cancer Outcomes.

(Chang A, Sloan EK, Antoni MH, Knight JM, Telles R, Lutgendorf SK.) Integr Cancer Ther. 2022;21:15347354221096081 PMID: 35579197 PMCID: PMC9118395 05/18/2022